Literature DB >> 31358473

Complex patterns of inheritance, including synergistic heterozygosity, in inborn errors of metabolism: Implications for precision medicine driven diagnosis and treatment.

Jerry Vockley1, Steven F Dobrowolski2, Georgianne L Arnold3, Ruben Bonilla Guerrero4, Terry G J Derks5, David A Weinstein6.   

Abstract

Inborn errors of metabolism have traditionally been viewed as the quintessential single gene disorders; defects in one gene leads to loss of activity of one enzyme causing a metabolic imbalance and clinical disease. However, reality has never been quite that simple, and the classic "one gene-one enzyme" paradigm has been upended in many ways. Multiple gene defects can lead to the same biochemical phenotype, often with different clinical symptoms. Additionally, different mutations in the same gene can cause variable phenotypes, often most dramatic when a disease can be identified by pre-symptomatic screening. Moreover, response to therapy is not homogeneous across diseases and specific mutations. Perhaps the biggest deviation from traditional monogenic inheritance is in the setting of synergistic heterozygosity, a multigenic inheritance pattern in which mutations in multiple genes in a metabolic pathway lead to sufficient disruption of flux through the pathway, mimicking a monogenic disorder caused by homozygous defects in one gene in that pathway. In addition, widespread adoption of whole exome and whole genome sequencing in medical genetics has led to the realization that individual patients with apparently hybrid phenotypes can have mutations in more than one gene, leading to a mixed genetic disorder. Each of these situations point to a need for as much precision as possible in diagnosing metabolic disease, and it is likely to become increasingly critical to drive therapy. This article examines examples in traditional monogenic disorders that illustrates these points and define inborn errors of metabolism as complex genetic traits on the leading edge of precision medicine.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2019        PMID: 31358473      PMCID: PMC8931500          DOI: 10.1016/j.ymgme.2019.07.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  60 in total

Review 1.  Newborn screening of metabolic disorders: recent progress and future developments.

Authors:  Piero Rinaldo; James S Lim; Silvia Tortorelli; Dimitar Gavrilov; Dietrich Matern
Journal:  Nestle Nutr Workshop Ser Pediatr Program       Date:  2008

2.  Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial.

Authors:  Cary O Harding; R Stephen Amato; Mary Stuy; Nicola Longo; Barbara K Burton; John Posner; Haoling H Weng; Markus Merilainen; Zhonghua Gu; Joy Jiang; Jerry Vockley
Journal:  Mol Genet Metab       Date:  2018-03-18       Impact factor: 4.797

3.  START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.

Authors:  Jeanine R Jarnes Utz; Cindy Pham Lorentz; Dorothy Markowitz; Kyle D Rudser; Brenda Diethelm-Okita; David Erickson; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2011-10-29       Impact factor: 4.797

4.  Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.

Authors:  J Vockley; J Charrow; J Ganesh; M Eswara; G A Diaz; E McCracken; R Conway; G M Enns; J Starr; R Wang; J E Abdenur; J Sanchez-de-Toledo; D L Marsden
Journal:  Mol Genet Metab       Date:  2016-08-27       Impact factor: 4.797

5.  Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.

Authors:  Rachel Mills; Susanne B Haga
Journal:  Pharmacogenomics       Date:  2013-06       Impact factor: 2.533

6.  Individualized long-term outcomes in blood phenylalanine concentrations and dietary phenylalanine tolerance in 11 patients with primary phenylalanine hydroxylase (PAH) deficiency treated with Sapropterin-dihydrochloride.

Authors:  Sylvia Stockler-Ipsiroglu; Nataliya Yuskiv; Ramona Salvarinova; Delia Apatean; Gloria Ho; Barbara Cheng; Alette Giezen; Yolanda Lillquist; Keiko Ueda
Journal:  Mol Genet Metab       Date:  2014-12-03       Impact factor: 4.797

7.  Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

Authors:  Harvey L Levy; Andrzej Milanowski; Anupam Chakrapani; Maureen Cleary; Philip Lee; Friedrich K Trefz; Chester B Whitley; François Feillet; Annette S Feigenbaum; Judith D Bebchuk; Heidi Christ-Schmidt; Alex Dorenbaum
Journal:  Lancet       Date:  2007-08-11       Impact factor: 79.321

8.  Evaluation of glycogen storage disease as a cause of ketotic hypoglycemia in children.

Authors:  Laurie M Brown; Michelle M Corrado; Rixt M van der Ende; Terry G J Derks; Margaret A Chen; Sara Siegel; Kate Hoyt; Catherine E Correia; Christopher Lumpkin; Theresa B Flanagan; Caroline T Carreras; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2014-07-29       Impact factor: 4.982

Review 9.  Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective.

Authors:  Katarzyna Drozda; Michael A Pacanowski; Christian Grimstein; Issam Zineh
Journal:  JACC Basic Transl Sci       Date:  2018-08-28

10.  Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.

Authors:  John A Phillips; Justin S Poling; Charles A Phillips; Krista C Stanton; Eric D Austin; Joy D Cogan; Lisa Wheeler; Chang Yu; John H Newman; Harry C Dietz; James E Loyd
Journal:  Genet Med       Date:  2008-05       Impact factor: 8.822

View more
  3 in total

1.  Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders.

Authors:  Evgenia Sklirou; Ahmad N Alodaib; Steven F Dobrowolski; Al-Walid A Mohsen; Jerry Vockley
Journal:  Front Genet       Date:  2021-01-15       Impact factor: 4.599

2.  Oxygraphy Versus Enzymology for the Biochemical Diagnosis of Primary Mitochondrial Disease.

Authors:  Matthew J Bird; Isabelle Adant; Petra Windmolders; Ingrid Vander Elst; Catarina Felgueira; Ruqaiah Altassan; Sarah C Gruenert; Bart Ghesquière; Peter Witters; David Cassiman; Pieter Vermeersch
Journal:  Metabolites       Date:  2019-10-10

3.  Variants in the ethylmalonyl-CoA decarboxylase (ECHDC1) gene: a novel player in ethylmalonic aciduria?

Authors:  Sarah Fogh; Graziana Dipace; Anne Bie; Maria Veiga-da-Cunha; Jakob Hansen; Margrethe Kjeldsen; Signe Mosegaard; Antonia Ribes; Niels Gregersen; Lars Aagaard; Emile Van Schaftingen; Rikke K J Olsen
Journal:  J Inherit Metab Dis       Date:  2021-06-08       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.